| Ytd | -14.35% | |
| 1y | -42.21% |
| Open | 18.92 | Prev Close | 18.71 | Low | 18.55 | High | 19.05 | Mkt Cap | 3.62B |
| Vol | 1.39M | Avg Vol | 2.37M | EPS | -0.52 | P/E | N/A | Forward P/E | 17.73 |
| Beta | 0.57 | Short Ratio | 7.43 | Inst. Own | 56.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 19.76 | 200-d Avg | 22.35 | 1yr Est | 46.35 |
LEGN News
JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers th
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Annual program will award funding to early-career healthcare professionals advancing research, educa
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned a consen
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curat
Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curat
Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective i
BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Le
Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previ
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today a
Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenali
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Lege
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATA
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight
TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the p
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perf
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers
With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall S
Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday mid
Legend Biotech NASDAQ: LEGN reported second-quarter 2026 results marked by continued global growth f
Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst c
The most oversold health care stocks present a buying opportunity. RSI indicator compares stock stre
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a
Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report)'s share price gapped down
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob
BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg
On July 15, J&J, a Legend Biotech Corporation partner, announced continued strong demand for Carvykt
UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre
JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announce
RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and
Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get th
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 1% on Thursday.
US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.
Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg
Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a glob
BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Leg
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with rel
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with re
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Lege
UBS analyst Ashwani Verma maintains Legend Biotech (NASDAQ:LEGN) with a Buy and raises the price
Top Wall Street analysts changed outlook on top names. For all rating changes, upgrades and downgrad